Anagha Abhijit Joshi

This inventor holds 7 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignee: Exelixis, Inc.. Active years: 2010-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anagha Abhijit Joshi. Retrieved from https://idiyas.com/inventor/anagha-abhijit-joshi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 8)

% Patents Active = 85.7

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 16.7

ph-index = 3

Forward Citations = 55(Granted Patents)

Company Filing History:

7 out of 177

Exelixis, Inc.

patents

Years Active: 2010-2023

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11597699 - MEK inhibitors and methods of their use (2023-03-07),

2. 8697737 - Raf modulators and methods of use (2014-04-15),

3. 8648066 - Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture (2014-02-11),

4. 8362002 - Azetidines as MEK inhibitors for the treatment of proliferative diseases (2013-01-29),

5. 7915250 - Azetidines as MEK inhibitors for the treatment of proliferative diseases (2011-03-29),

6. 7846959 - Raf modulators and methods of use (2010-12-07),

7. 7803839 - Azetidines as MEK inhibitors for the treatment of proliferative diseases (2010-09-28),

Title: Anagha Abhijit Joshi: Innovator in Cancer Treatment

Introduction

Anagha Abhijit Joshi is a prominent inventor based in Fremont, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target cancer treatment. With a total of 7 patents to his name, Joshi's work is paving the way for innovative therapies.

Latest Patents

Among his latest patents, Joshi has developed MEK inhibitors and methods of their use. These compounds, which are classified under Formula (I), are designed to treat proliferative diseases such as cancer. The invention includes pharmaceutical compositions containing these compounds and outlines methods for their application in cancer treatment. Another notable patent involves Raf modulators and methods of use. This invention relates to compounds that modulate protein kinase enzymatic activity, influencing cellular activities such as proliferation and programmed cell death. The compounds are particularly effective in treating kinase-dependent diseases and conditions.

Career Highlights

Anagha Joshi is currently employed at Exelixis, Inc., where he continues to advance his research in cancer therapies. His work is characterized by a commitment to developing innovative solutions that address critical health challenges.

Collaborations

Joshi collaborates with esteemed colleagues, including Neel Kumar Anand and Charles M Blazey, to further enhance the impact of his research and inventions.

Conclusion

Anagha Abhijit Joshi's contributions to the field of cancer treatment through his innovative patents highlight his role as a leading inventor. His ongoing work at Exelixis, Inc. continues to inspire advancements in medical science.

Profile summary based on public USPTO records.